ArticleIndian journal of surgical oncology2025
A Single-Institution Audit of Chemo-PORT Placements During Breast Surgery with Literature Review for Management of Common Complications.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most breast cancer patients need chemotherapy for a duration of 3-12 months. The morbidity of frequent intravenous access, mainly on the contralateral upper limb is troublesome and chemo-PORT placement is helpful. We analysed a prospective database of patients who had concurrent chemo-PORT placement with breast surgery between January-2019 and December-2023 at our centre for their complication rate. Clinico-pathological data was collected from electronic medical records and analysed in SPSS-V25. A total of 408 breast cancer patients underwent chemo-PORT placement. The median age of cohort was 50 years(18-78). Breast conservation surgery was done in 201(49.3%), 207(51.7%) had mastectomy. Of 408, 195(47.8%) patients had per primum surgery, 126(30.9%), 26(6.4%) and 61(15%) were operated post-1st line chemotherapy, in the recurrent setting and for second breast primary respectively. 260(63.7%) were HER2 positive, 73 ER/PgR + (17.9%) and 75(18.4%) TNBC. Total 256(62.7%) patients received anti-HER2 therapy. The overall complication rate was 12.5%(51/408). Procedural/immediate complications were seen in 3/408(0.7%) patients which included pericardial placement, pleural cavity placement with haemothorax, and intra-operative guidewire migration in 1 patient each. Post-procedural complications were further sub-classified- as short-term complications that included PORT site hematomas in 3/408(0.7%), pocket-site infections in 4/408(0.9%); and long-term complications that included catheter-related bloodstream infections in 13/408(3.2%), catheter related thrombosis in 7/408(1.7%), persistent withdrawal occlusion in 14/408(3.4%), and catheter displacement in 7/408(1.7%).Chemo-PORT placement is an efficient and safe way of administering chemotherapy in breast cancer patients with < 1% serious complication rate. However, timely identification of serious complications can prevent a catastrophe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.